| Recruitment status | Terminated |
| Unique ID issued by UMIN | UMIN000008061 |
| Receipt No. | R000009498 |
| Official scientific title of the study | Domestic collaborative research of Genome-wide association study (GWAS) in predicting the therapeutic responce and adversed effect of new anticancer drugs for hepatocellular carcinoma. |
| Date of disclosure of the study information | 2012/07/01 |
| Last modified on | 2018/12/04 (Ver. 7) |
| Basic information | ||
| Official scientific title of the study | Domestic collaborative research of Genome-wide association study (GWAS) in predicting the therapeutic responce and adversed effect of new anticancer drugs for hepatocellular carcinoma. | |
| Title of the study (Brief title) | New anticancer drugs for hepatocellular carcinoma and GWAS | |
| Region |
|
|
| Condition | ||
| Condition | Hepatocellular carinoma | |
| Classification by specialty |
|
|
| Classification by malignancy | Malignancy | |
| Genomic information | YES | |
| Objectives | |
| Narrative objectives1 |
To identify genetic factor associated with therapeutic responce and adversed effect of new anticancer drug for hepatocellular carcinoma by use of genome-wide association study (GWAS) |
| Basic objectives2 | Others |
| Basic objectives -Others | Relationship between genetic factor and therapeutic response / adversed effect to new anticancer drugs for the treatment of hepatocellular carcinoma |
| Trial characteristics_1 | Exploratory |
| Trial characteristics_2 | |
| Developmental phase | Not applicable |
| Assessment | |
| Primary outcomes | Relationship between genetic factor and therapeutic response / adversed effect to new anticancer drugs for the treatment of hepatocellular carcinoma |
| Key secondary outcomes | |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Single arm |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Uncontrolled |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 1 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | New anticancer drugs for the treatment of hepatocellular carcinoma approved after April 2009 | |
| Interventions/Control_2 | ||
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | Patients with hepatocellular carcinoma who were treated by new anticancer drugs for the treatment of hepatocellular carcinoma approved after April 2009 | |||
| Key exclusion criteria | Patients whom the physicians in charge judge their enrollment inappropriate | |||
| Target sample size | 300 | |||
| Research contact person | |
| Name of lead principal investigator | Shuichi Kaneko |
| Organization | Graduate School of Medical Sciences, Kanazawa University |
| Division name | Disease Control and Homeostasis |
| Address | 13-1 Takara-machi, Kanazawa, Ishikawa 920-8641, JAPAN |
| TEL | 076-265-2233 |
| s-kaneko@m-kanazawa.jp | |
| Public contact | |
| Name of contact person | Shuichi Kaneko |
| Organization | Graduate School of Medical Sciences, Kanazawa University |
| Division name | Disease Control and Homeostasis |
| Address | 13-1 Takara-machi, Kanazawa, Ishikawa 920-8641, JAPAN |
| TEL | 076-265-2000 |
| Homepage URL | |
| s-kaneko@m-kanazawa.jp | |
| Sponsor | |
| Institute | Disease Control and Homeostasis, Graduate School of Medical Sciences, Kanazawa University |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Graduate School of Medical Sciences, Kanazawa University |
| Organization | |
| Division | |
| Category of Funding Organization | Self funding |
| Nationality of Funding Organization | Japan |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | 独立行政法人・国立国際医療肝炎センター(東京都),東京大学大学院医学系研究科・人類遺伝学教室(東京都),福井大学(福井県),愛媛大学(愛媛県),鳥取大学(鳥取県),千葉大学(千葉県),山口大学(山口県),大阪大学(大阪府),杏林大学(東京都),山形大学(山形県),昭和大学(東京都),兵庫医科大学(兵庫県),近畿大学(大阪府),岐阜大学(岐阜県),岡山大学(岡山県),久留米大学(福岡県),財団法人佐々木研究所附属杏雲堂病院(東京府),福井県済生会病院(福井県),埼玉医科大学(埼玉県),およびそれらの関連施設 |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Terminated | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry |
|
||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000009498 |